Search Result

Results for "

Binding assay

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (3) 5-HT Receptor (4) Adrenergic Receptor (5) Androgen Receptor (4) Angiotensin Receptor (3) Apoptosis (6) ATP Citrate Lyase (1) Autophagy (1) Bcl-2 Family (2) Beta-secretase (1) c-Myc (1) Cholecystokinin Receptor (2) CXCR (3) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (2) FLAP (2) Glucocorticoid Receptor (1) GPR84 (1) Histone Methyltransferase (6) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (4) LIM Kinase (LIMK) (1) LPL Receptor (2) mAChR (1) MDM-2/p53 (3) mTOR (1) Opioid Receptor (3) Orexin Receptor (OX Receptor) (1) PD-1/PD-L1 (2) PPAR (1) Prostaglandin Receptor (2) RAR/RXR (1) Ras (2) ROR (1) sFRP-1 (2) Smo (3) Somatostatin Receptor (1) Thrombin (1) TNF Receptor (1) Vasopressin Receptor (1) Wee1 (1)
By Research Areas:	Cancer (33) Cardiovascular Disease (13) Endocrinology (8) Infection (3) Inflammation/Immunology (19) Metabolic Disease (10) Neurological Disease (10)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Biochemical Assay Reagents Penicillin-binding protein (PBP) FKBP FABP Transthyretin (TTR) Ligands for Target Protein for PROTAC YB-1 GHR P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19381

WAY-151932 VNA-932; WAY-VNA 932	Vasopressin Receptor	Metabolic Disease Endocrinology
WAY-151932 is a vasopressin V₂-receptor agonist with IC₅₀ of 80.3 nM and 778 nM in human-V₂ binding and V_1a binding assay.

HY-136379

CID44216842 1 Publications Verification Cdc42-IN-1	Ras	Cancer
CID44216842 (Cdc42-IN-1) is a potent Cdc42-selective guanine nucleotide binding lead inhibitor. The EC₅₀s for Cdc42 WT and Cdc42Q61L mutant are 1.0 and 1.2 μM in GTP binding assay, respectively. The EC₅₀s for Cdc42 WT and Cdc42Q61L mutant are 0.3 and 0.5 μM in GDP binding assay, respectively. Use as a molecular probe .

HY-16582A

Sonidegib 5 Publications Verification Erismodegib; LDE225; NVP-LDE225	Smo	Cancer
Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC₅₀ of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively .

HY-16582

Sonidegib diphosphate 5 Publications Verification Erismodegib diphosphate; LDE225 diphosphate; NVP-LDE225 diphosphate	Smo	Cancer
Sonidegib diphosphate (Erismodegib diphosphate) is a potent and selective Smo antagonist with IC₅₀ of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively .

HY-P0179

β-Casomorphin, bovine β-Casomorphin-7 (bovine); Bovine β-casomorphin-7	Opioid Receptor	Neurological Disease Metabolic Disease
β-Casomorphin, bovine (β-Casomorphin-7 (bovine) ) is a opioid peptide with an IC₅₀ of 14 μM in an Opioid receptors binding assay .

HY-13466

MK-4256 2 Publications Verification	Somatostatin Receptor	Metabolic Disease Endocrinology
MK-4256 is a potent and selective SSTR3 antagonist with IC₅₀s of 0.66 nM and 0.36 nM in human and mouse receptor binding assays, respectively.

HY-116065

CUMI-101	5-HT Receptor	Neurological Disease
CUMI-101 (compound 8) is a 5-HT_1AR agonist (K_i=0.15 nM) with an EC₅₀ of 0.1 nM in the [35S]GTPγS binding assay. CUMI-101 can be used in the research of neurological diseases .

HY-147366

RBP4 ligand-1	Others	Metabolic Disease
RBP4 ligand-1 is a non-retinoid ligands for (RBP4) retinol-binding protein 4. The hRBP4_SPA IC₅₀ and RBP4–TTR FRET IC₅₀ values are 0.23±0.11 and 0.13±0.12 μM in the radioligand binding assay and FRET assay, respectively .

HY-128466

N-Biotinyl-L-cysteine	Biochemical Assay Reagents	Others
N-Biotinyl-L-cysteine is a biotinylated biochemical assay reagent, which is used to detect avidin and biotin through a competitive binding reaction .

HY-123434

PD-149164	Cholecystokinin Receptor	Metabolic Disease Endocrinology
PD-149164 is a potent agonist of cholecystokinin B (CCK-B) receptor, with IC₅₀ values of 0.083 nM and 75 nM in binding assay to CCK-B and CCK-A .

HY-P0179A

β-Casomorphin, bovine TFA β-Casomorphin-7 (bovine) (TFA); Bovine β-casomorphin-7 TFA	Opioid Receptor	Neurological Disease Metabolic Disease
β-Casomorphin, bovine TFA (β-Casomorphin-7 (bovine) TFA) is a opioid peptide with an IC₅₀ of 14 μM in an Opioid receptors binding assay .

HY-B1486

Oxprenolol hydrochloride 1 Publications Verification Ba 39089	Adrenergic Receptor	Cardiovascular Disease
Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a K_i of 7.10 nM in a radioligand binding assay using rat heart muscle .

HY-16582AS

Sonidegib-d4 Erismodegib-d₄; LDE225-d₄; NVP-LDE225-d₄	Isotope-Labeled Compounds	Others
Sonidegib-d4 is a isotope of Sonidegib. Sonidegib is a potent and selective Smo antagonist with IC₅₀ of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively .

HY-U00423

CRTH2-IN-1 Ramatroban analog	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
CRTH2-IN-1 (Ramatroban analog) is a selective prostaglandin D2 receptor DP2 (CRTH2) antagonist with an IC₅₀ of 6 nM in a human DP2 binding assay.

HY-112157

PF-06751979 1 Publications Verification	Beta-secretase	Neurological Disease
PF-06751979 is a potent, brain penetrant, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC₅₀ of 7.3 nM in BACE1 binding assay.

HY-128128

ASN04421891	Others	Neurological Disease
ASN04421891 is a potent GPR17 receptor modulator, with an EC₅₀ of 3.67 nM in [35S]GTPγS binding assay. ASN04421891 can be used for neurodegenerative diseases research .

HY-B1486A

Oxprenolol Ba 39089 free base	Adrenergic Receptor	Cardiovascular Disease
Oxprenolol (Ba 39089 free base) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a K_i of 7.10 nM in a radioligand binding assay using rat heart muscle .

HY-153728

WM-586	Histone Methyltransferase	Cancer
WM-586 is a covalent WDR5 inhibitor that disrupts the binding of WDR5 to MYC. WM-586 specifically decreases cellular WDR5 and MYC interaction with the IC₅₀ of 101 nM in HTRF assay .

HY-120760

L-691831	Others	Others
L-691831 is a ligand for 5-lipoxygenase activating protein binding assays that has utility as a tool for studying 5-lipoxygenase activating protein (FLAP) related activities. L-691831 can be used to measure the affinity of FLAP on the leukocyte membrane for leukotriene synthesis inhibitors, with binding being correlated with inhibition of leukotriene synthesis.

HY-128111

ASN02563583	Others	Neurological Disease
ASN02563583, a compound that regulates the activity of the GPR17 receptor, has a IC₅₀ value of 0.64 nM in [₃₅S]GTPγS binding assay. ASN02563583 can be used in the study of neurological diseases .

HY-145817A

lunresertib 1 Publications Verification RP-6306	Wee1	Cancer
lunresertib (RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC₅₀ of 14 nM. lunresertib shows a high degree of selectivity over other kinases in cellular binding assays. lunresertib shows anticancer effects .

HY-144397

LEO 134310	Glucocorticoid Receptor	Inflammation/Immunology
LEO 134310 is a selective, non-steroidal glucocorticoid receptor (GR) agonist optimized for topical research., LEO 134310 showed high affinity (EC₅₀ of 14 nM) in a GR binding assay. LEO 134310 can be used for skin diseases .

HY-10858

WAY 316606 4 Publications Verification	sFRP-1	Cancer
WAY 316606 is an inhibitor of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt. The affinity of WAY-316606 for sFRP-1 is determined using the FP binding assay with IC₅₀ of 0.5 μM .

HY-10858A

WAY 316606 hydrochloride	sFRP-1	Cancer
WAY 316606 hydrochloride is an inhibitor of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt. The affinity of WAY-316606 for sFRP-1 is determined using the FP binding assay with IC₅₀ of 0.5 μM .

HY-144784

CXCR2 antagonist 7	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 7 (compound 19) is a potent CXCR2 antagonist. CXCR2 antagonist 7 shows potent CXCR2 binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM) ^{[ 1]}.

HY-144783

CXCR2 antagonist 6	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 6 (compound 35c) is a potent CXCR2 antagonist. CXCR2 antagonist 6 shows potent CXCR2 binding affinity (IC₅₀=0.044 µM) and calcium mobilization (IC₅₀=0.66 µM) ^{[ 1]}.

HY-144781

CXCR2 antagonist 5	CXCR	Inflammation/Immunology Cancer
CXCR2 antagonist 5 (compound 25) is a potent CXCR2 antagonist. CXCR2 antagonist 5 shows potent CXCR2 binding affinity (IC₅₀=0.013 µM) and calcium mobilization (IC₅₀=0.1 µM) ^{[ 1]}.

HY-15682

TTNPB 4 Publications Verification Ro 13-7410; Arotinoid acid; AGN191183	RAR/RXR Autophagy Apoptosis	Cancer
TTNPB is a highly potent RAR agonist. Competitive binding assays using human RARs yield IC₅₀s of α=5.1 nM, β= 4.5 nM, and γ=9.3 nM, respectively.

HY-B1486S

Oxprenolol-d7 hydrochloride Ba 39089-d₇	Adrenergic Receptor	Cardiovascular Disease
Oxprenolol-d₇ (hydrochloride) is the deuterium labeled Oxprenolol hydrochloride. Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-14442

ML 10302 hydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
ML 10302 hydrochloride is a potent and selective 5-HT₄ receptor agonist, with an EC₅₀ of 4 nM. ML 10302 hydrochloride displays more than 680-fold selectivity over 5-HT₃ receptor in binding assay .

HY-13928

GW0742 Maximum Cited Publications 14 Publications Verification GW610742	PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 is a potent PPARβ and PPARδ agonist, with an IC₅₀ of 1 nM for human PPARδ in binding assay, and EC₅₀s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

HY-160292

Enoltasosartan	Angiotensin Receptor	Cardiovascular Disease
Enoltasosartan is an angiotensin II (AngII) receptor blocker .

HY-119544

Ripisartan UP-2696	Angiotensin Receptor	Cardiovascular Disease
Ripisartan (UP-2696) is an angiotensin II receptor antagonist. Ripisartan is orally available. Ripisartan binds to angiotensin II receptors, dilates blood vessels, and lowers blood pressure .

HY-16999

RO8994	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
RO8994 (Compound 4) is an orally active, highly potent and selective spiroindolinone p53-MDM2 inhibitor with an IC₅₀ value of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays). RO8994 induces up-regulation of p53 expression and Apoptosis in wild-type p53 cancer cells. RO8994 also inhibits tumor growth in the tumor xenograft model .

HY-B1486AS

Oxprenolol-d7	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease
Oxprenolol-d₇ is the deuterium labeled Oxprenolol. Oxprenolol (Ba 39089 free base) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-115510

SPR inhibitor 3 SPRi3	Others	Inflammation/Immunology
SPR inhibitor 3 (SPRi3) is a potent sepiapterin reductase (SPR) inhibitor. SPR inhibitor 3 (SPRi3) displays high binding affinity to human SPR in a cell-free assay (IC₅₀=74 nM) and efficiently reduces biopterin levels in a cell-based assay (IC₅₀=5.2 μM). SPR inhibitor 3 (SPRi3) reduces neuropathic and inflammatory pain through a reduction of BH4 levels .

HY-12220A

MM-102 TFA 4 Publications Verification HMTase Inhibitor IX TFA	Histone Methyltransferase	Cancer
MM-102 TFA (HMTase Inhibitor IX TFA) is a potent WDR5/MLL interaction inhibitor, achieves IC50 = 2.4 nM with an estimated Ki < 1 nM in WDR5 binding assay, which is >200 times more potent than the ARA peptide.

HY-14460

AM679	FLAP	Inflammation/Immunology
AM679 is a potent, selective 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC₅₀ of 2 nM in a human FLAP membrane binding assay. AM679 markedly reduces the respiratory syncytial virus-driven ocular pathology as well as the synthesis of cysteinyl leukotrienes (CysLTs) in the eye .

HY-103663

MAK683 2 Publications Verification	Histone Methyltransferase	Cancer
MAK683 is an embryonic ectoderm development (EED) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC₅₀s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay .

HY-14250A

(Rac)-PF-998425	Androgen Receptor	Endocrinology
(Rac)-PF-998425 is a potent, selective, nonsteroidal androgen receptor (AR) antagonist. (Rac)-PF-998425 has IC₅₀ values of 26 and 90 nM in the AR binding and cellular assays, respectively. (Rac)-PF-998425 has the potential for the research of the androgenetic alopecia .

HY-103663A

MAK683 hydrochloride	Histone Methyltransferase	Cancer
MAK683 hydrochloride is an embryonic ectoderm development (EED) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC₅₀s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay .

HY-P1096

A71623	Cholecystokinin Receptor	Metabolic Disease
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC₅₀s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .

HY-107587

A-286982 2 Publications Verification	Integrin	Inflammation/Immunology
A-286982 is a potent and allosteric LFA-1/ICAM-1 interaction inhibitor with IC₅₀s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding and LFA-1-mediated cellular adhesion assay, respectively .

HY-108507

MRT-10	Smo	Cancer
MRT-10 is a seven-transmembrane receptor smoothened (Smo) antagonist with an IC₅₀ of 0.65 μM in the micromolar range in various Hedgehog (Hh) assays. MRT-10 binds to the Smo receptor at the level of the Bodipycyclopamine binding site. MRT-10 can be used for the research of cancer .

HY-126077

MTI-31 LXI-15029	mTOR	Inflammation/Immunology Cancer
MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (K_d: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC₅₀ of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer .

HY-149005

PRMT5-IN-19	Histone Methyltransferase	Cancer
PRMT5-IN-19 (Compound 41) is an selective orally active non-nucleoside PRMT5 inhibitor with IC₅₀ values of 23.9 nM (radioactive biochemical assay) and 47 nM (AlphaLISA assay). PRMT5-IN-19 can occupy the *SAM-binding* pocket in PRMT5 and block methyltransferase activity, which displays good selectivity over other PRMTs and PKMTs. PRMT5-IN-19 inhibits cell proliferation by inducing cell apoptosis**, and can be used for cancer-related research .

HY-151884

FUBP1-IN-2	c-Myc	Cancer
FUBP1-IN-2 (compound 9) is a potent FUBP1 (far upstream binding protein 1) inhibitor. FUBP1-IN-2 inhibits the KH4 FUBP1-FUSE interaction in a gel shift assay. FUBP1-IN-2 binds to FUBP1 in a ChIP assay. FUBP1-IN-2 reduces both c-Myc mRNA and protein expression, increases p21 mRNA and protein expression, and depletes intracellular polyamines .

HY-127111

NDI-091143 2 Publications Verification	ATP Citrate Lyase	Cancer
NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC₅₀ of 2.1 nM (ADP-Glo assay), a K_i of 7.0 nM and a K_d of 2.2 nM. NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate .

HY-120635

BMS-1001 hydrochloride	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC₅₀ value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM .

HY-14250

PF-998425	Androgen Receptor	Endocrinology
PF-998425 is a potent, selective nonsteroidal androgen receptor (AR) antagonist with an IC₅₀ of 37 nM and 43 nM in AR binding and cellular assays, respectively. PF-998425 has low activity on common receptors and enzymes, such as progesterone receptor. PF-998425 can be used for sebum control and androgenetic alopecia research .

Cat. No.	Product Name

HY-L0115V

Asinex Macrocycles Library

10,091 compounds

ASINEX has elaborated a library of diverse macrocycles using an effective tool box of synthetic methods. The resulting scaffolds are novel, tremendously diverse, medchem-relevant, macrocyclic frameworks.

Macrocyles tend to be larger than traditional screening molecules which make them perfect discovery tools for targets with shallow or extended binding sites. At the same time, their unique character based on restricted flexibility and ability to form intra-molecular hydrogen bonds allows for design approaches effectively optimizing properties such asaqueous solubility and membrane permeability. Many of these macrocycles have been tested for aqueous and DMSO solubility with cut-offs applied at 10 mM in DMSO and 50 µM in PBS (pH 7.4) followed by PAMPA permeability assay.

Cat. No.	Product Name	Type

HY-D0014

Brilliant blue G-250

3 Publications Verification

Indicators

Brilliant Blue G-250 is a dye commonly used for the visualization of proteins separated by SDS-PAGE, offering a simple staining procedure and high quantitation. In the Bradford protein assay, protein concentrations are determined by the absorbance at 595 nm due to the binding of Brilliant Blue G-250 to proteins. Brilliant Blue G-250 is a safe highly selective P2×7R antagonist with promising consequent inactivation of NLRP3 inflammasome .

HY-128466

N-Biotinyl-L-cysteine	Biochemical Assay Reagents
N-Biotinyl-L-cysteine is a biotinylated biochemical assay reagent, which is used to detect avidin and biotin through a competitive binding reaction .

Cat. No.	Product Name	Target	Research Area

HY-P0179

β-Casomorphin, bovine β-Casomorphin-7 (bovine); Bovine β-casomorphin-7	Opioid Receptor	Neurological Disease Metabolic Disease
β-Casomorphin, bovine (β-Casomorphin-7 (bovine) ) is a opioid peptide with an IC₅₀ of 14 μM in an Opioid receptors binding assay .

HY-P1096

A71623	Cholecystokinin Receptor	Metabolic Disease
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC₅₀s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .

HY-P1376A

G-Protein antagonist peptide TFA	mAChR Adrenergic Receptor	Endocrinology
G-Protein antagonist peptide TFA is a truncated substance P-related peptide, competes with receptor for G protein binding. G-Protein antagonist peptide TFA inhibits the activation of G_i or G_o by M2 muscarinic cholinergic receptor (M2 mAChR) or of G_s by beta-adrenergic receptor in the reconstituted phospholipid vesicles, assayed by receptor-promoted GTP hydrolysis .

HY-P5367

5-FAM-PMDM6 PMDM6-F	Peptides	Others
5-FAM-PMDM6 (PMDM6-F) is a biological active peptide. (PMDM6-F is a fluorescent-labeled probe for MDM2-binding assay.)

HY-P5908F

FAM-DEALA-Hyp-YIPD	Peptides	Others
FAM-DEALA-Hyp-YIPD is a fluorescent HIF-1α peptide, with the K_d of 180-560 nM. FAM-DEALA-Hyp-YIPD can be used to assess VHL binding in Fluorescence Polarization (FP) displacement assay, and evaluate the effect of VHL binding on degradation activity .

HY-P0179A

β-Casomorphin, bovine TFA β-Casomorphin-7 (bovine) (TFA); Bovine β-casomorphin-7 TFA	Opioid Receptor	Neurological Disease Metabolic Disease
β-Casomorphin, bovine TFA (β-Casomorphin-7 (bovine) TFA) is a opioid peptide with an IC₅₀ of 14 μM in an Opioid receptors binding assay .

Cat. No.	Product Name	Target	Research Area

HY-P9949

Reslizumab Sch 55700	Interleukin Related	Inflammation/Immunology
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with K_D values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-126115

15(S)-Latanoprost 15-epi Latanoprost	Cardiovascular Disease Classification of Application Fields Disease Research Fields	Others
15(S)-Latanoprost is an analog of latanoprost in which the hydroxyl at carbon 15 is inverted relative to latanoprost. The IC₅₀ values for the free acid forms of latanoprost and 15(S)-latanoprost were determined to be 3.6 nM and 24 nM, respectively, in a FP receptor binding assay using the cat iris sphincter muscle. A 3 μg dose of 15(S)-latanoprost caused a 1 mmHg reduction of IOP in normotensive cynomolgus monkeys.

HY-116161

Bimatoprost isopropyl ester	Cardiovascular Disease Classification of Application Fields Disease Research Fields	Others
15(R)-17-phenyl trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl trinor PGF2α isopropyl ester) is the latanoprost-related isomer containing both a double bond at 13,14 and an inverted (β) hydroxyl group at C-15. Similar to 15(S)-latanoprost, 15(R)-17-phenyl trinor PGF2α isopropyl ester is a potential impurity in most commercial preparations of the latanoprost bulk drug product. The IC₅₀ values for the free acid forms of 15(S)-17-phenyl trinor PGF2α and 15(R)-17-phenyl trinor PGF2α were determined to be 0.71 nM and 30 nM, respectively, in a FP receptor binding assay using the cat iris sphincter muscle.1 A 3 μg dose of 15(R)-17-phenyl trinor PGF2α caused a 1.9 mmHg reduction of IOP in normotensive cynomolgus monkeys.

Cat. No.	Product Name	Chemical Structure

HY-B1486S

Oxprenolol-d7 hydrochloride
Oxprenolol-d₇ (hydrochloride) is the deuterium labeled Oxprenolol hydrochloride. Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-10569S1

Ponesimod-d7

Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation .

HY-16582AS

Sonidegib-d4
Sonidegib-d4 is a isotope of Sonidegib. Sonidegib is a potent and selective Smo antagonist with IC₅₀ of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively .

HY-B1486AS

Oxprenolol-d7
Oxprenolol-d₇ is the deuterium labeled Oxprenolol. Oxprenolol (Ba 39089 free base) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-10569S

Ponesimod-d4
Ponesimod-d₄ (ACT-128800-d₄)is the deuterium labeledPonesimod(HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

Cat. No.	Product Name		Classification

HY-158385

5-Azido-PEG4-SS-UTP tristriethylamine		Azide
5-Azido-PEG4-SS-UTP tristriethylamine is a biochemical assay reagent, which can be used in click chemistry. Click chemistry has great potential for use in binding between nucleic acids, lipids, proteins, and other molecules, and has been used in many research fields because of its beneficial characteristics, including high yield, high specificity, and simplicity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks